Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The most common founder pathogenic variant c.868G > A (p.Val290Met) in the NPHS2 gene in a representative adult Czech cohort with focal segmental glomerulosclerosis is associated with a milder disease and its underdiagnosis in childhood.
Thomasová D, Zelinová M, Libik M, Geryk J, Votýpka P, Rajnochová Bloudíčková S, Krejčí K, Reiterová J, Jančová E, Machová J, Kollárová M, Rychík I, Havrda M, Horáčková M, Putzová M, Šafránek R, Kollár M, Macek M Jr. Thomasová D, et al. Among authors: havrda m. Front Med (Lausanne). 2023 Dec 19;10:1320054. doi: 10.3389/fmed.2023.1320054. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38170106 Free PMC article.
Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study.
Zavada J, Pesickova S, Rysava R, Olejarova M, Horák P, Hrncír Z, Rychlík I, Havrda M, Vítova J, Lukác J, Rovensky J, Tegzova D, Böhmova J, Zadrazil J, Hána J, Dostál C, Tesar V. Zavada J, et al. Among authors: havrda m. Lupus. 2010 Oct;19(11):1281-9. doi: 10.1177/0961203310371155. Epub 2010 Jul 6. Lupus. 2010. PMID: 20605876 Clinical Trial.
Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A.
Závada J, Sinikka Pesicková S, Rysavá R, Horák P, Hrncír Z, Lukác J, Rovensky J, Vítová J, Havrda M, Rychlík I, Böhmova J, Vlasáková V, Slatinská J, Zadrazil J, Olejárová M, Tegzova D, Tesar V. Závada J, et al. Among authors: havrda m. Lupus. 2014;23(1):69-74. doi: 10.1177/0961203313511555. Epub 2013 Nov 8. Lupus. 2014. PMID: 24213308
Clinical case: idelalisib-induced immunoglobulin flare.
Novak J, Havrda M, Gaherova L, Spicka J, Kozak T. Novak J, et al. Among authors: havrda m. Immunopharmacol Immunotoxicol. 2017 Aug;39(4):251-252. doi: 10.1080/08923973.2017.1318912. Epub 2017 May 19. Immunopharmacol Immunotoxicol. 2017. PMID: 28523957
46 results